Medical Health & Life Science Research News

Research delivers insight into the global congestive heart failure (heart failure) drugs market

The report provides comprehensive information on the therapeutics under development for Congestive Heart Failure (Heart Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Additionally, the report provides an overview of key players involved in therapeutic development for Congestive Heart Failure (Heart Failure)   and features dormant and discontinued projects.      

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Complete report on Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2016 addition with 99 market data tables and 16 figures, spread across 393 pages is available at…ew-h2-2016.html

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, Investor presentations and featured press releases from company/university sites and industry-specific third party sources.

- Agency -.

Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis

Drug Profile Discussed /Mentioned in this Research:

sacubitril + valsartan, AAVS-100A1, ACP-01, AdipoCell, aladorian sodium, ALD-201, AMG-986, AntimiR-199a, ARX-720, BAY-868050, BBR-12, beperminogene perplasmid, BMS-986231, bucindolol hydrochloride, C-21, C3BSCQR-1, CAP-1002, Carfostin, carvedilol CR, carvedilol phosphate CR, cenderitide, cibinetide, CLR-325,Drug to Inhibit Calpain for Heart Failure, elamipretide, enalapril maleate, F-373280, GDF-11, istaroxime, ivabradine hydrochloride, JVS-100, KBP-5074, milrinone ER, neladenoson bialanate, Neucardin

Companies Discussed /Mentioned in this Research:

Amgen Inc., AnGes MG, Araim Pharmaceuticals, ARCA biopharma, Ascelegen Therapeutics, Asterias Biotherapeutics, Athersys, Bayer AG, BEAT BioTherapeutics Corp., BioCardia, Bristol-Myers Squibb Company, Capricor Therapeutics, Cell Therapy Limited,Celyad SA, Eli Lilly and Company, FibroGen, GlaxoSmithKline Plc, Glucox Biotech AB, Heart Metabolics Limited, Hemostemix Ltd, Innopharmax Inc., Jiangsu Hengrui Medicine Co., Juventas Therapeutics, La Jolla Pharmaceutical Company, Laboratoires Pierre Fabre SA, Mast Therapeutics,



  • The report provides a snapshot of the global therapeutic landscape of Congestive Heart Failure (Heart Failure)
  • The report reviews pipeline therapeutics for Congestive Heart Failure (Heart Failure) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Congestive Heart Failure (Heart Failure)  therapeutics and enlists all their major and minor projects
  • The report assesses Congestive Heart Failure (Heart Failure)  therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Congestive Heart Failure (Heart Failure)

Reasons to access

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Congestive Heart Failure (Heart Failure)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Congestive Heart Failure (Heart Failure)    pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline